Blog Archives
Va-C-Nemus reassures on the safety of vaccination against Covid-19 in NMD
Launched in 2021, the Va-C-Nemus national prospective observational study involved 1,020 adults with a neuromuscular disease of genetic or autoimmune origin, 18% of whom were on corticosteroid and/or immunosuppressive therapy, 20% on respiratory assistance and 5% with cardiac involvement. After one year of post-vaccination follow-up : the type and frequency of adverse events were similar … [Read more]
M&M’s – Muscle Monday Seminar – 23 June – Eric Allemand (France)
Regulation of transcriptome diversity through alternative splicing in hematological genetic disorders Monday 23 June 2025 – 12h00-13h00 Eric Allemand, PhD (Imagine Institute, Paris, France) More information on the presentation and the speaker On prior registration for people outside the Institute of Myology: medecine-umrs974-myologie@sorbonne-universite.fr M&M’s seminar organised by the Center of Research in Myology, at the Institute of … [Read more]
A look back at the 3rd edition of ‘Muscle Week’
The 3ᵉ edition of Muscle Week, organised from 2 to 8 June 2025 by the Institute of Myology and AFM-Téléthon, mobilised researchers, healthcare professionals, the world of sport, businesses, local authorities and the general public around a major public health issue: muscle, the key organ in our lives and our general good health. At … [Read more]
Seeing our muscles in action – Interview with Constantin Slioussarenko
Constantin Slioussarenko, an engineer by training, is a researcher in the NMR and Spectroscopy Laboratory, co-directed by Harmen Reyngoud and Benjamin Marty, at the Neuromuscular Investigation Center. The team works on neuromuscular diseases that affect all the muscles in the body, and whose progression can be fairly heterogeneous, making it difficult to monitor their progress … [Read more]
Building the Muscle Atlas – Interview with Bruno Cadot
Bruno Cadot is head of research in the ‘Signalling pathways and striated muscles’ team led by Antoine Muchir at the Center of Research in Myology . His work has led him to make extensive use of imaging to study muscle and to collaborate with the Institute’s Morphological unit*, which produces and studies sections of patient … [Read more]
The evolution of the new Morimoto-Ruy-Malicdan syndrome described in two brothers
In a previous study published in 2024, Marie Morimoto et al. described nine cases of a new congenital myopathy linked to biallelic variants of the RFC4 gene, the Morimoto-Ruy-Malicdan syndrome. This syndrome is characterised by coordination problems, muscular and respiratory weakness, hearing impairment, weight loss and cerebellar atrophy. A new study of two brothers of … [Read more]
Towards a reassessment of certain contraindications to the use of drugs in autoimmune myasthenia gravis
American researchers have investigated the possible complications associated with the use of several classes of antibiotics known to be harmful to myasthenia gravis patients: data from patients followed between 2002 and 2022 in Cleveland (USA) and taking ciprofloxacin, levofloxacin (both fluoroquinolones) or azithromycin, were analysed retrospectively. The main endpoint was the occurrence of decompensation of … [Read more]
The association of dermatomyositis and encephalopathy is exceptional but should be noted
Mexican clinicians report the clinical and immunological data of three patients with concomitant encephalopathy and dermatomyositis (DM): the three patients were adults in their fifties with no previous history of the disease, all met the criteria for dermatomyositis, including the presence of myositis-specific antibodies (in particular MDA5, Mi2 and TIF1g), the clinical picture included sub-acute … [Read more]
Rising incidence of motor neurone disease in France before the Covid-19 crisis
Using data from the French National Health Data System (SNDS), a French team has carried out a study of changes in the incidence of motor neurone disease between 2010 and 2023. During this period, 30,028 new cases of motor neurone disease were recorded, with an average of 2,145 new cases per year. The crude incidence … [Read more]
No additional long-term beneficial effects for the bisoprolol-perindopril combination
British clinicians report the long-term results of a prophylactic treatment for cardiomyopathy in Duchenne muscular dystrophy (DMD): the combination of perindopril (a conversion enzyme inhibitor) and bisoprolol (a beta-blocker) had already been the focus of an initial randomised clinical trial by the same team in 2011 in children with DMD aged between 5 and 13 … [Read more]
